Sanctuary Advisors LLC Has $2.12 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Sanctuary Advisors LLC increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 80.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,039 shares of the biopharmaceutical company’s stock after purchasing an additional 16,511 shares during the period. Sanctuary Advisors LLC’s holdings in Halozyme Therapeutics were worth $2,120,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HALO. International Assets Investment Management LLC acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at $33,000. GAMMA Investing LLC grew its holdings in shares of Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares during the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth about $49,000. Toth Financial Advisory Corp bought a new position in Halozyme Therapeutics during the 3rd quarter valued at about $57,000. Finally, FSC Wealth Advisors LLC bought a new position in Halozyme Therapeutics during the 3rd quarter valued at about $65,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 3.6 %

NASDAQ:HALO opened at $46.84 on Thursday. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The firm has a market capitalization of $5.96 billion, a price-to-earnings ratio of 15.51, a PEG ratio of 0.43 and a beta of 1.23. The business’s 50-day moving average price is $51.20 and its two-hundred day moving average price is $54.14.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler increased their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. JMP Securities lifted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. HC Wainwright restated a “buy” rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday. Finally, JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $61.11.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $56.34, for a total value of $563,400.00. Following the completion of the transaction, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at approximately $38,127,756.96. This represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 30,000 shares of company stock valued at $1,621,800. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.